key: cord-0834344-z6u9had2
authors: Mazzone, Antonino; Castelnovo, Laura; Tamburello, Antonio; Gatti, Arianna; Brando, Bruno; Faggioli, Paola; Mumoli, Nicola
title: Monocytes could be a bridge from inflammation to thrombosis on COVID‐19 injury: a case report
date: 2020-08-26
journal: nan
DOI: 10.1016/j.tru.2020.100007
sha: 95856eb71cdd3b807e559d301fabb4d76f7605ee
doc_id: 834344
cord_uid: z6u9had2

• Inflammation and thrombotic events are frequent but also coronary thrombosis occurring during acute coronary syndromes are due to an inflammatory storm with increased number of circulating activated monocytes/macrophages. • We have mapped the expression of CD11b/CD18 in monocytes/macrophages of a COVID19 patient. • In vivo acute inflammatory response, induced by the virus, and the subsequent cytokine release stimulates the up-regulation of CD11b/CD18 that favors thrombosis. • The overproduction of early response proinflammatory results in an inflammatory storm, leading to an increased risk of vascular hyperpermeability, multiorgan failure, and death. • Advances in cytokine biology and molecular biology have led to the development of novel immunologic approaches to the treatment of COVID19 lung injury that target the cytokine. • Increasing expression of CD11b/CD18 induced by COVID19 play a key role in in bridging inflammation and thrombosis.

SARS-Cov2 infection is responsible for pandemic COVID19, a new viral illness causing acute respiratory syndrome and cardiovascular events (1) in which inflammation and thrombotic events are frequent. It's also known that exacerbated inflammation ad immune system dysregulation can cause severe clinical manifestations; in this process a crucial effector role is played by monocytes.

Coronary thrombosis occurring during acute coronary syndromes, similarly, are due to an inflammatory storm with increased number of circulating activated monocytes/macrophages (2) .

We know that monocytes are involved in infections: persistent activation of circulating monocytes/macrophages, induced by the release of cytokines, above all IL-6, has been postulated (1); moreover IL-6 overexpression seems to be related with disease severity and pro-coagulant profile. Prior observations documented that inflammation mediated by phagocytes in rat lungs is blocked by preincubation with anti-Mo1 monoclonal antibodies thus preventing pulmonary injury (3); these antibodies react with CD11b/CD18 integrin complex, that represents a major adhesion on monocytes/macrophages and IL6 promotes interaction with ICAM, also acting on platelets, to favor thrombosis (4, 5) . The relationship between inflammatory process and heart disease has been debated: monocytes/macrophages recruitment express the CD11b/CD18 adhesion molecule, mediating their adhesion to the endothelial cells and leading to inflammation. Therefore, as reported in ischemic diseases and unstable angina, activated leukocytes and platelets potentiate each other's effects, favoring the occurrence of thrombosis (1). A paper of Altieri (7) clarify these aspects: binding of soluble clotting factor X to CD11b/CD18. The physiological significance of factor X and fibrinogen binding with activated CD11b/CD18 in vivo, is one of the possible bridges between inflammation and thrombosis. Autopsy studies in patients affected by SARS-CoV2 pneumonia demonstrate that inflammation, vasculitis and thrombosis are the pathogenetic mechanism of ARDS and subsequent death. So, in an effort to investigate the interface between coagulation and inflammation, we have mapped the expression of CD11b/CD18 in monocytes/macrophages of a COVID19 patient. In vivo acute inflammatory response, induced by the virus, and the subsequent cytokine release stimulates the up-regulation of CD11b/CD18 that favors thrombosis. We know that the role of anti IL6 drugs on the regulation of the expression of CD11bCD/18 on monocytes macrophages was previously studied in inflammation in atherosclerosis and in myocardial ischemia; our data, even in light of our recent work (6), and once completed, could help to demonstrate the hypothesis that the interaction between CD11b/CD18, endothelial cells platelets, factor X and fibrinogen plays a fundamental role in favoring inflammation and thrombosis. The overproduction of early response proinflammatory results in what has been described as an inflammatory storm, leading to an increased risk of J o u r n a l P r e -p r o o f vascular hyperpermeability, multiorgan failure, and death. Advances in cytokine biology and molecular biology leaded to the development of novel immunologic approaches to the treatment of COVID19 lung injury; increasing expression of CD11b/CD18 induced by COVID19 may play a key role in bridging inflammation and thrombosis.

J o u r n a l P r e -p r o o f

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

C-reactive protein increase in unstable coronary disease cause or effect?

Prevention of pulmonary injury in isolated perfused rat lungs by activated human neutrophils preincubated with anti-Mo1 monoclonal antibody

Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease

Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: a bridge between inflammation and coagulation